Review of NICE Technology Appraisal Guidance No.214; Bevacizumab in combination with a taxane for the first line treatment of metastatic breast cancer

Proposal to move guidance to the static list

The planned date for review of the above guidance is July 2013.

This is the date at which the Institute considers whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

We have found no new evidence that will affect the recommendations made in the original guidance. Consequently we propose that the guidance become static.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial. Please see appendix A for a full list of the organisations we have contacted. 

July 2013